Additionally, PI3KCA mutations, PTEN loss or both, leading to PI3K activation, are related to tumor progression and reduced survival rate in breast cancer, which has an adverse effect on the therapeutic effect of trastuzumab (Razis et al., 2011) (Figure 3). This evidence concerns the gene PIK3CD and breast cancer.